Topics
News
CME/CE
Editorial Advisory Board
Partnerships
The Science Behind Using Circulating Tumor DNA for MCC
In this second part of a 4 part video series, Lisa Zaba, MD, PhD, FAAD, explains the data behind the clinical trials on using circulating tumor DNA for merkel cell carcinoma (MCC). She expands on her talk from the 2022 American Academy of Dermatology Annual Meeting.
Related Videos
Related Content
